TransMedics Group (NASDAQ:TMDX) Director David Weill Sells 3,571 Shares

Key Points

• Director David Weill sold 3,571 shares on March 4 at an average of $146.82 for a total of $524,294, leaving him with 12,134 shares — a 22.74% reduction in his holdings (SEC filing).
• Shares fell $10.27 to $129.80 on heavy volume (1.08M vs. avg 822K), trading below the 50‑day moving average ($135.35) but slightly above the 200‑day ($126.90).
• The stock has a consensus rating of "Moderate Buy" with an average price target of $150.67, while major institutions (including Goldman Sachs) have recently increased their stakes and several analysts raised price targets up to $175.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director David Weill sold 3,571 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total transaction of $524,294.22. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,781,513.88. This represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

TransMedics Group Stock Performance

Shares of TransMedics Group stock traded down $10.27 during trading on Friday, hitting $129.80. 1,079,448 shares of the stock were exchanged, compared to its average volume of 822,516. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average price of $135.35 and a 200-day moving average price of $126.90. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. TransMedics Group, Inc. has a 1-year low of $62.23 and a 1-year high of $156.00.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada raised its stake in shares of TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after buying an additional 868 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Envestnet Asset Management Inc. lifted its position in TransMedics Group by 12.6% during the second quarter. Envestnet Asset Management Inc. now owns 26,298 shares of the company's stock valued at $3,524,000 after buying an additional 2,933 shares during the period. Finally, Atria Investments Inc purchased a new position in TransMedics Group during the 2nd quarter valued at about $213,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMDX has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. lifted their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 25th. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a "buy" rating in a research report on Wednesday, December 17th. Finally, Oppenheimer raised their price objective on TransMedics Group from $150.00 to $175.00 and gave the company an "outperform" rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.